



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: 17 January, 2023

<b>To</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
<b>Security Code: 540596</b>	<b>Symbol: ERIS</b>

**SUBJECT: INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

Dear Sir/Madam,

In accordance with the requirement of regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A (1) of Part A of Schedule III and SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, details attached herein may be taken on record

The details of the same will be uploaded on the website of the Company.

Thanking You,

**For Eris Lifesciences Limited**

\_\_\_\_\_  
**Milind Talegaonkar**  
**Company Secretary & Compliance Officer**  
**Membership No: A26493**

**Encl: As above**

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



### Annexure I

**Acquisition(s)(including agreement to acquire), Scheme of Arrangement (amalgamation/ merger/ demerger/restructuring), or sale or disposal of any unit(s), division(s) or subsidiary of the listed entity or any other restructuring:**

<b>Acquisition (including agreement to acquire):</b>		
a)	Name of the target entity, details in brief such as size, turnover etc.	<p><u>Target Entity: -</u> Part of the dermatology portfolio of Glenmark Pharmaceuticals Limited by way of acquisition of 9 (Nine) trademarks along with their applicable line extensions (collectively referred to as “<b>Brands</b>”) by Eris Oaknet Healthcare Private Limited (“<b>EOHPL</b>”), a wholly owned subsidiary of the listed entity (“<b>Transaction</b>”).</p> <p><u>Consideration: -</u> INR 340 Crores.</p> <p><u>Turnover: -</u> INR 87.30 Crores for FY 2021-2022</p>
b)	whether the acquisition would fall within related party transaction(s)and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length”;	<p>No. The transaction is at arms-length.</p>
c)	Industry to which the entity being acquired belongs;	<p>Pharmaceutical Industry.</p> <p>Only a part of the dermatology portfolio is being acquired through the Transaction.</p>
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	<p>EOHPL is the entity which focuses on the dermatology segment business of the listed entity.</p> <p>The Transaction helps augment and expand the business of EOHPL by way of expansion in product offerings</p>
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
f)	Indicative time period for completion of the acquisition	The Transaction stands completed as on the date of disclosure.

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
 Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



g)	nature of consideration -whether cash consideration or share swap and details of the same;	Cash Consideration									
h)	cost of acquisition or the price at which the shares are acquired	INR 340 crores									
i)	percentage of shareholding / control acquired and / or number of shares acquired;	Not applicable									
j)	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p><u>Brief background: -</u> The Transaction is related to formulations falling in the group - topical dermatological antifungals, plain topical corticosteroids, topical antipsoriasis products, demelanising agents.</p> <p><u>Date of Incorporation: -</u> Not applicable</p> <p><u>History of last 3 years Turnover of the Brands:</u></p> <table border="1" data-bbox="869 952 1516 1064"> <thead> <tr> <th colspan="3">Turnover of the Brands</th> </tr> <tr> <th>FY 19- 20</th> <th>FY 20- 21</th> <th>FY 21- 22</th> </tr> </thead> <tbody> <tr> <td>INR 91.10 Cr</td> <td>INR 80.60 Cr</td> <td>INR 87.30 Cr</td> </tr> </tbody> </table> <p><u>Country: -</u> The Transaction is primarily intended for India business of EOHPL.</p>	Turnover of the Brands			FY 19- 20	FY 20- 21	FY 21- 22	INR 91.10 Cr	INR 80.60 Cr	INR 87.30 Cr
Turnover of the Brands											
FY 19- 20	FY 20- 21	FY 21- 22									
INR 91.10 Cr	INR 80.60 Cr	INR 87.30 Cr									

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
 Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867